➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
Colorcon
Merck
Boehringer Ingelheim

Last Updated: July 23, 2021

DrugPatentWatch Database Preview

MESTINON Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Mestinon patents expire, and what generic alternatives are available?

Mestinon is a drug marketed by Bausch and is included in four NDAs.

The generic ingredient in MESTINON is pyridostigmine bromide. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Mestinon

A generic version of MESTINON was approved as pyridostigmine bromide by IMPAX LABS on April 24th, 2003.

  Try it Free

Drug patent expirations by year for MESTINON
Drug Prices for MESTINON

See drug prices for MESTINON

Recent Clinical Trials for MESTINON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranPhase 2/Phase 3
Aarhus University HospitalPhase 4
University of AarhusPhase 4

See all MESTINON clinical trials

Pharmacology for MESTINON

US Patents and Regulatory Information for MESTINON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch MESTINON pyridostigmine bromide INJECTABLE;INJECTION 009830-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bausch MESTINON pyridostigmine bromide TABLET;ORAL 009829-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bausch MESTINON pyridostigmine bromide SYRUP;ORAL 015193-001 Approved Prior to Jan 1, 1982 AA RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bausch MESTINON pyridostigmine bromide TABLET, EXTENDED RELEASE;ORAL 011665-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
Colorcon
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.